Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW-ALC-2
2025-522312-16-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Modality
- Peptides
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in alcohol use disorder (AUD) comparing Brenipatide with Placebo comparator (2 arms). Primary endpoint: Change in drinking patterns in alcohol use disorder. Planned start Feb 2026; status: authorised.
02
Drugs
brenipatide
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on 2025-522312-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522312-16-00.